Bioxyne (ASX:BXNDA) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


ASX:BXNDA Bioxyne Ltd ASX:BXNDA
50 GF Score
Price A$0.95
GF Value A$0.69
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Bioxyne Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Bioxyne's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

ASX:BXNDA vs KHC, GIS: Margin of Safety % (DCF Earnings Based) Comparison

For the Packaged Foods subindustry, Bioxyne's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioxyne Margin of Safety % (DCF Earnings Based) vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Bioxyne's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Bioxyne's Margin of Safety % (DCF Earnings Based) falls into.


ASX:BXNDA
50GF Score
Bioxyne Ltd ASX:BXNDA
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bioxyne (ASX:BXNDA) Overvalued in 2026?

Based on GuruFocus' analysis, Bioxyne stock appears to be overvalued. The current stock price of A$0.95 is trading 37.7% above its estimated GF Value™ of A$0.69. GuruFocus considers Bioxyne to be Significantly Overvalued.

Key valuation signals for ASX:BXNDA:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: A$0.69 vs. price of A$0.95 (37.7% above fair value)
  • GF Score™: 50/100 with 8 warning signs

No single metric tells the full story. See the ASX:BXNDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioxyne Business Description

Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
50GF Score

Get the complete analysis for ASX:BXNDA

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.95
Price
A$0.69
GF Value